- Last week, Inventiva (NASDAQ:IVA) announced a licensing and collaboration agreement with Sino Biopharm’s subsidiary Chia Tai-Tianqing Pharmaceutical Group (CTTQ) to develop and commercialize lanifibranor in Greater China.
- Regardless of CTTQ’s decision on lanifibranor’s clinical development pathway in China, HC Wainwright notes that Sino Biopharm is a vertically-integrated company with substantial R&D, manufacturing, sales, and marketing capability.
- The analyst regards the collaboration as a financially prudent pathway for lanifibranor’s expansion to a major NASH market, given Sino Biopharm’s experience as a commercial-stage company in Greater China.
- HC Wainwright affirms a Buy rating but lowered the price target from $42 to $36 based on the expected enrollment delay for the pivotal Phase 3 NATiV3 trial.
- The analyst adjusted the projected sales trajectory of lanifibranor for the treatment of NASH to reflect the latest clinical timeline (last patient’s first visit in 2H23, and top-line data readout in 2H25).
- These changes reduced the analyst’s projected peak revenues of lanifibranor in NASH to €1.7 billion in 2034 (previously €1.9 billion).
- Price Action: IVA shares are up 0.26% at $3.93 on the last check Monday.
Global Weed Brand To Buy Australian Vaporizes For $1.7M In Shares
Cannabis company Flora Growth Corp. (NASDAQ: FLGC) has signed a definitive agreement Monday to buy Australian Vaporizers Pty Limited from a health-tech company, Lifeist Wellness Inc. (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company.
